Insider Transactions in Q1 2025 at Revolution Medicines, Inc. (RVMD)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
2,041
-3.42%
|
$77,558
$38.71 P/Share
|
|
Mar 17
2025
|
Xiaolin Wang |
SELL
Bona fide gift
|
Direct |
2,718
-2.59%
|
-
|
|
Mar 17
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
3,294
-1.11%
|
$128,466
$39.04 P/Share
|
|
Mar 17
2025
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,058
-1.95%
|
$119,262
$39.04 P/Share
|
|
Mar 17
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,864
-1.59%
|
$72,696
$39.04 P/Share
|
|
Mar 17
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
11,738
-2.59%
|
$457,782
$39.04 P/Share
|
|
Mar 17
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,458
-2.38%
|
$56,862
$39.04 P/Share
|
|
Mar 01
2025
|
Mark A Goldsmith |
BUY
Grant, award, or other acquisition
|
Direct |
97,400
+17.69%
|
-
|
|
Mar 01
2025
|
Xiaolin Wang |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+15.32%
|
-
|
|
Mar 01
2025
|
Lin Wei Chief Medical Officer |
SELL
Grant, award, or other acquisition
|
Direct |
20,800
-18.5%
|
-
|
|
Mar 01
2025
|
Margaret A Horn Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,600
+15.44%
|
-
|
|
Mar 01
2025
|
Stephen Michael Kelsey |
BUY
Grant, award, or other acquisition
|
Direct |
36,600
+10.99%
|
-
|
|
Mar 01
2025
|
Jack Anders Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,400
+14.86%
|
-
|
|
Mar 01
2025
|
Jeff Cislini General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+26.44%
|
-
|
|
Jan 21
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
2,406
-5.78%
|
$96,240
$40.5 P/Share
|